Treatment of CD4+ PBMCs with cyclic peptides derived from ICAM-1 (cIBR) or LFA-1 (cLABL)
Treatment . | Odds ratio*of MTOC polarization in Gag p19+ PBMCs vs Gag p19- PBMCs . | Polarization in Gag p19+ cells (%) . | P† . |
|---|---|---|---|
| Untreated control | 3.68 | 69 | |
| cIBR | 1.74 | 42 | <.001 |
| cLAB.L | 1.93 | 36 | .004 |
| cIBR + cLAB.L | 1.25 | 36 | <.001 |
Treatment . | Odds ratio*of MTOC polarization in Gag p19+ PBMCs vs Gag p19- PBMCs . | Polarization in Gag p19+ cells (%) . | P† . |
|---|---|---|---|
| Untreated control | 3.68 | 69 | |
| cIBR | 1.74 | 42 | <.001 |
| cLAB.L | 1.93 | 36 | .004 |
| cIBR + cLAB.L | 1.25 | 36 | <.001 |
Three independent experiments were performed with CD4+ PBMCs from 3 different HTLV-1-infected patients with HAM/TSP and high viral load. Where 2 cells formed a conjugate, the orientation of the MTOC was noted, and the odds ratio was calculated for polarization of the MTOC in infected versus uninfected cells.
Summary (weighted mean) odds ratio from the 3 experiments
Significance level of reduction in odds ratio compared with untreated control